Non-exclusive license for Solid Biosciences’ proprietary, next-generation myotropic capsid, AAV-SLB101, to accelerate development of KNA-155 for dysferlinopathy SEATTLE, September 23, 2025--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback